Product Description
Contact lenses for myopia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02366910)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Colombia
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07276347 |
CAMP | N/A |
Recruiting |
Myopia|Hyperopia |
2026-09-01 |
2025-12-12 |
Primary Endpoints |
|
NCT06884202 |
CLU484-P007 | N/A |
Completed |
Myopia |
2025-08-26 |
2025-09-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06483113 |
CLU484-N001 | N/A |
Terminated |
Hyperopia|Presbyopia|Astigmatism|Myopia |
2025-02-27 |
2025-07-22 |
Primary Endpoints |
|
NCT06308666 |
FOX | N/A |
Completed |
Myopia |
2024-10-23 |
2024-12-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06161012 |
CR-6553 | N/A |
Completed |
Other |
2024-02-13 |
2024-03-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06044948 |
CLU484-P003 | N/A |
Completed |
Other |
2023-11-08 |
2024-11-21 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT05805345 |
CLF993-P001 | N/A |
Withdrawn |
Astigmatism |
2023-05-01 |
2023-05-22 |
||
NCT05020990 |
C20-691 (EX-MKTG-121) | N/A |
Completed |
Astigmatism |
2022-09-30 |
2023-12-21 |
Primary Endpoints |
|
NCT05010512 |
CLU484-P002 | N/A |
Completed |
Myopia |
2021-10-12 |
2022-11-09 |
Primary Endpoints|Treatments |
|
NCT04567186 |
CR-6392 | N/A |
Completed |
Other |
2020-11-25 |
2021-12-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04037969 |
MALTESE | N/A |
Completed |
Keratoconjunctivitis Sicca |
2019-11-26 |
2021-04-24 |
Primary Endpoints|Treatments |
|
NCT03762668 |
CLP691-C002 | N/A |
Completed |
Hyperopia|Myopia |
2019-01-07 |
2020-01-08 |
Primary Endpoints|Treatments |
|
NCT03628599 |
CLS312-P001 | N/A |
Completed |
Myopia |
2018-09-25 |
2019-07-10 |
||
NCT03341923 |
CLJ369-P001 | N/A |
Completed |
Presbyopia |
2018-06-05 |
2019-03-21 |
Treatments |
|
NCT03305770 |
CLE383-C005 | N/A |
Completed |
Myopia |
2018-02-21 |
2019-03-21 |
Primary Completion Date|Start Date |
|
NCT03322423 |
CR-5860 | N/A |
Completed |
Other |
2017-11-04 |
2019-03-21 |
Treatments |
|
NCT03118934 |
CLK027-P001 | N/A |
Completed |
Presbyopia |
2017-07-07 |
2019-03-21 |
Treatments |
|
NCT02939170 |
CLO870-C001 | N/A |
Completed |
Ocular Discomfort |
2016-12-02 |
2019-03-21 |
Treatments |
|
NCT02871375 |
CLE914-P001 | N/A |
Completed |
Presbyopia|Myopia |
2016-11-14 |
2019-03-20 |
Treatments |
|
NCT02710292 |
CLS104-P001 | N/A |
Completed |
Other |
2016-09-14 |
2019-03-20 |
||
NCT02750813 |
CLV771-P001 | N/A |
Completed |
Other |
2016-08-17 |
2019-03-20 |
Treatments |
|
NCT02517567 |
CLT978-P001 | N/A |
Completed |
Other |
2016-04-22 |
2019-03-22 |
Treatments |
|
NCT02694835 |
CLP691-C001 | N/A |
Completed |
Ocular Discomfort |
2016-04-11 |
2019-03-20 |
||
NCT02595502 |
CR-5743 | N/A |
Completed |
Vision Disorders |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT02341859 |
JP-MKTG-201501 | N/A |
Completed |
Myopia |
2015-06-01 |
2019-03-20 |
Treatments |